Stock 6677 ANXO PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Anxo Pharmaceutical Co., Ltd.

Equities

6677

TW0006677008

Pharmaceuticals

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-07-04 pm EDT 		5-day change 1st Jan Change
43.15 TWD +0.58% Intraday chart for Anxo Pharmaceutical Co., Ltd. +0.12% -11.31%
Apr. 30 Anxo Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Anxo Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,535 1,432 1,376 1,185 1,426 2,708
Enterprise Value (EV) 1 2,308 2,240 2,057 1,853 2,071 3,200
P/E ratio 53.6 x 59.8 x 43.7 x 61.6 x -114 x 116 x
Yield - 0.75% - - - 0.82%
Capitalization / Revenue 1.81 x 1.63 x 1.59 x 1.44 x 1.65 x 2.88 x
EV / Revenue 2.72 x 2.55 x 2.38 x 2.25 x 2.39 x 3.4 x
EV / EBITDA 18.2 x 19.2 x 16.3 x 17.8 x 30.2 x 28.3 x
EV / FCF -42.3 x 69.4 x 42.8 x 41.5 x 33.3 x -22.9 x
FCF Yield -2.37% 1.44% 2.33% 2.41% 3% -4.37%
Price to Book 2.67 x 2.4 x 1.93 x 1.62 x 1.97 x 2.49 x
Nbr of stocks (in thousands) 44,882 44,882 48,164 48,164 48,164 55,664
Reference price 2 34.20 31.90 28.57 24.60 29.60 48.65
Announcement Date 4/30/19 4/30/20 4/26/21 4/27/22 4/27/23 4/30/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 849.9 877.9 866.1 824.1 866.3 939.9
EBITDA 1 126.6 116.9 126.4 104.2 68.53 113.1
EBIT 1 52.33 45.24 57.12 40.1 5.945 53.31
Operating Margin 6.16% 5.15% 6.6% 4.87% 0.69% 5.67%
Earnings before Tax (EBT) 1 39.12 29.41 48.91 24.33 -4.714 38.68
Net income 1 28.65 24.12 31.4 19.23 -12.56 21.86
Net margin 3.37% 2.75% 3.63% 2.33% -1.45% 2.33%
EPS 2 0.6380 0.5333 0.6536 0.3993 -0.2607 0.4200
Free Cash Flow 1 -54.58 32.25 48.03 44.62 62.13 -139.9
FCF margin -6.42% 3.67% 5.55% 5.41% 7.17% -14.88%
FCF Conversion (EBITDA) - 27.58% 37.99% 42.84% 90.66% -
FCF Conversion (Net income) - 133.73% 152.94% 231.98% - -
Dividend per Share - 0.2381 - - - 0.4000
Announcement Date 4/30/19 4/30/20 4/26/21 4/27/22 4/27/23 4/30/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 773 808 681 668 646 492
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 6.103 x 6.91 x 5.39 x 6.416 x 9.424 x 4.354 x
Free Cash Flow 1 -54.6 32.3 48 44.6 62.1 -140
ROE (net income / shareholders' equity) 4.31% 3.13% 5.15% 2.4% -0.85% 3.03%
ROA (Net income/ Total Assets) 1.74% 1.49% 1.87% 1.31% 0.19% 1.59%
Assets 1 1,648 1,621 1,682 1,471 -6,582 1,375
Book Value Per Share 2 12.80 13.30 14.80 15.20 15.00 19.60
Cash Flow per Share 2 3.430 3.960 4.310 4.450 5.010 5.310
Capex 1 47 23.9 16 34.8 14.6 57.8
Capex / Sales 5.53% 2.72% 1.84% 4.23% 1.68% 6.15%
Announcement Date 4/30/19 4/30/20 4/26/21 4/27/22 4/27/23 4/30/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
ANXO PHARMACEUTICAL CO., LTD. Stock Anxo Pharmaceutical Co., Ltd.
-11.31% 73.52M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+56.89% 809B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+39.52% 624B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.55% 351B
ABBVIE INC. Stock AbbVie Inc.
+7.92% 289B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.74% 240B
NOVARTIS AG Stock Novartis AG
+13.83% 220B
ROCHE HOLDING AG Stock Roche Holding AG
-0.49% 219B
AMGEN INC. Stock Amgen Inc.
+7.94% 166B
PFIZER, INC. Stock Pfizer, Inc.
-2.57% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 6677 Stock
  4. Financials Anxo Pharmaceutical Co., Ltd.